MA45149A - Méthodes de traitement de la maladie d'alzheimer - Google Patents
Méthodes de traitement de la maladie d'alzheimerInfo
- Publication number
- MA45149A MA45149A MA045149A MA45149A MA45149A MA 45149 A MA45149 A MA 45149A MA 045149 A MA045149 A MA 045149A MA 45149 A MA45149 A MA 45149A MA 45149 A MA45149 A MA 45149A
- Authority
- MA
- Morocco
- Prior art keywords
- alzheimer
- disease
- treatment
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662346818P | 2016-06-07 | 2016-06-07 | |
| US201662435531P | 2016-12-16 | 2016-12-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA45149A true MA45149A (fr) | 2019-04-10 |
Family
ID=59067640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA045149A MA45149A (fr) | 2016-06-07 | 2017-06-06 | Méthodes de traitement de la maladie d'alzheimer |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20200308259A1 (https=) |
| EP (1) | EP3464350A1 (https=) |
| JP (3) | JP2019517540A (https=) |
| KR (2) | KR20190021311A (https=) |
| CN (3) | CN114796481A (https=) |
| AU (2) | AU2017276656A1 (https=) |
| BR (1) | BR112018075300A2 (https=) |
| CA (1) | CA3026598A1 (https=) |
| IL (1) | IL263433B2 (https=) |
| MA (1) | MA45149A (https=) |
| MX (1) | MX2018015022A (https=) |
| WO (1) | WO2017211827A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201827467A (zh) | 2016-11-03 | 2018-08-01 | 比利時商健生藥品公司 | 焦穀胺酸類澱粉蛋白－β之抗體及其用途 |
| EP3696192A1 (en) | 2019-02-15 | 2020-08-19 | Consejo Superior De Investigaciones Científicas | Therapeutic target and monoclonal antibodies against it for the diagnosis and treatment of alzheimer´s disease |
| US20220177560A1 (en) | 2019-03-26 | 2022-06-09 | Janssen Pharmaceutica Nv | Antibodies to Pyroglutamate Amyloid-B and Uses Thereof |
| CN110511276A (zh) * | 2019-08-13 | 2019-11-29 | 王跃驹 | 植物作为宿主在表达Aducanumab抗体中的应用 |
| MX2022004678A (es) * | 2019-10-22 | 2022-08-15 | Biogen Ma Inc | Anticuerpo anti-beta amiloide para el tratamiento de la enfermedad de alzheimer. |
| MX2023000949A (es) | 2020-07-23 | 2023-02-22 | Othair Prothena Ltd | Anticuerpos anti-beta-amiloide (abeta). |
| KR102321601B1 (ko) * | 2020-11-19 | 2021-11-05 | 주식회사 휴런 | 뇌 영상을 이용한 알츠하이머병의 생물학적 분류 장치 및 방법 |
| WO2022261026A2 (en) * | 2021-06-07 | 2022-12-15 | Biogen Ma Inc. | Methods for treating alzheimer's disease |
| US20250122146A1 (en) * | 2021-09-30 | 2025-04-17 | The Scripps Research Institute | Compounds for reducing neuroinflammation |
| MX2024005999A (es) * | 2021-11-19 | 2024-05-30 | Ap Biosciences Inc | Anticuerpos bispecificos dirigidos a cd137 y usos de los mismos para la inmunoterapia anticancer. |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2468770T (lt) * | 2006-07-14 | 2018-05-25 | Ac Immune S.A. | Humanizuotas antikūnas prieš beta amiloidą |
| KR20120017469A (ko) | 2007-01-05 | 2012-02-28 | 유니버시티 오브 취리히 | 질환 특이적 결합 분자 및 표적을 제공하는 방법 |
| BR112013008765B8 (pt) | 2010-10-11 | 2023-05-02 | Biogen Idec Int Neuroscience Gmbh | Anticorpos monoclonais anti-tau humano isolados ou um fragmento de ligação à tau dos mesmos, métodos de preparação dos mesmos, polinucleotídeo ou polinucleotídeos, vetor ou vetores, composição, método in vitro de diagnóstico ou monitoramento da progressão de uma tauopatia neurodegenerativa em um indivíduo humano, método in vitro para diagnosticar uma tauopatia neurodegenerativa em um indivíduo humano, e kit útil para o diagnóstico de uma tauopatia neurodegenerativa |
| RU2689674C2 (ru) * | 2012-10-15 | 2019-05-28 | Медиммьюн Лимитед | Антитела к бета-амилоиду |
| CN105979962A (zh) * | 2012-12-07 | 2016-09-28 | 比奥根国际神经科学公司 | 使用抗Aβ抗体减少脑淀粉样蛋白斑块的方法 |
| PT2935326T (pt) | 2012-12-21 | 2020-09-14 | Biogen Ma Inc | Anticorpos anti-tau humanos |
| RU2724190C2 (ru) * | 2014-02-08 | 2020-06-23 | Дженентек, Инк. | Способы лечения болезни альцгеймера |
| MA41115A (fr) * | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
-
2017
- 2017-06-06 CA CA3026598A patent/CA3026598A1/en active Pending
- 2017-06-06 MA MA045149A patent/MA45149A/fr unknown
- 2017-06-06 KR KR1020197000443A patent/KR20190021311A/ko not_active Ceased
- 2017-06-06 AU AU2017276656A patent/AU2017276656A1/en not_active Abandoned
- 2017-06-06 CN CN202210397569.0A patent/CN114796481A/zh active Pending
- 2017-06-06 CN CN201780044190.9A patent/CN109476730A/zh active Pending
- 2017-06-06 WO PCT/EP2017/063711 patent/WO2017211827A1/en not_active Ceased
- 2017-06-06 MX MX2018015022A patent/MX2018015022A/es unknown
- 2017-06-06 EP EP17730427.6A patent/EP3464350A1/en active Pending
- 2017-06-06 BR BR112018075300-9A patent/BR112018075300A2/pt unknown
- 2017-06-06 JP JP2018563815A patent/JP2019517540A/ja not_active Withdrawn
- 2017-06-06 US US16/307,364 patent/US20200308259A1/en not_active Abandoned
- 2017-06-06 CN CN202210397435.9A patent/CN114931635A/zh active Pending
- 2017-06-06 KR KR1020237040938A patent/KR20230165883A/ko not_active Ceased
- 2017-06-06 IL IL263433A patent/IL263433B2/en unknown
-
2022
- 2022-02-25 US US17/681,011 patent/US20220281963A1/en not_active Abandoned
- 2022-08-15 JP JP2022129326A patent/JP2022145965A/ja not_active Withdrawn
-
2024
- 2024-08-29 AU AU2024216442A patent/AU2024216442A1/en active Pending
-
2025
- 2025-07-25 JP JP2025124966A patent/JP2025160337A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019517540A (ja) | 2019-06-24 |
| IL263433B2 (en) | 2024-03-01 |
| US20200308259A1 (en) | 2020-10-01 |
| AU2017276656A1 (en) | 2018-12-13 |
| AU2024216442A1 (en) | 2024-10-17 |
| JP2022145965A (ja) | 2022-10-04 |
| CN114931635A (zh) | 2022-08-23 |
| WO2017211827A1 (en) | 2017-12-14 |
| CA3026598A1 (en) | 2017-12-14 |
| JP2025160337A (ja) | 2025-10-22 |
| KR20190021311A (ko) | 2019-03-05 |
| CN109476730A (zh) | 2019-03-15 |
| KR20230165883A (ko) | 2023-12-05 |
| EP3464350A1 (en) | 2019-04-10 |
| IL263433A (en) | 2019-01-31 |
| MX2018015022A (es) | 2019-08-14 |
| US20220281963A1 (en) | 2022-09-08 |
| IL263433B1 (en) | 2023-11-01 |
| CN114796481A (zh) | 2022-07-29 |
| BR112018075300A2 (pt) | 2019-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3645121A4 (en) | METHOD OF TREATMENT FOR HUNTINGTON'S MORBUS | |
| MA45149A (fr) | Méthodes de traitement de la maladie d'alzheimer | |
| EP3515505A4 (en) | AAV TREATMENT BY MORBUS ALZHEIMER | |
| MA41115A (fr) | Procédé de traitement de la maladie d'alzheimer | |
| EP3458589A4 (en) | COMPOSITIONS AND METHODS FOR TREATING MORBUS HUNTINGTON | |
| EP3291815A4 (en) | METHOD FOR TREATING A NEURODEEGENERATIVE DISEASE | |
| EP3490582A4 (en) | METHOD AND COMPOSITIONS FOR TREATING MYELOFIBROSE | |
| EP3813808A4 (en) | Methods of treating substance abuse | |
| EP3644996A4 (en) | METHOD OF TREATMENT FOR HUNTINGTON'S MORBUS | |
| EP3534907A4 (en) | COMPOSITIONS AND METHODS FOR TREATING LIVER DISEASES | |
| EP3528852A4 (en) | METHOD AND COMPOSITIONS FOR TREATING MORBUS FABRY | |
| EP3294345A4 (en) | TPP1 FORMULATIONS AND METHOD FOR THE TREATMENT OF CLN2 DISEASES | |
| EP3019523A4 (en) | METHOD FOR THE TREATMENT OF MORBUS ALZHEIMER AND MORBUS HUNTINGTON | |
| EP3377118A4 (en) | METHOD FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES | |
| EP3386520A4 (en) | METHOD FOR THE TREATMENT OF EYE DISEASES OR DISORDERS | |
| EP3402533A4 (en) | METHOD AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | |
| EP3846830A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MUSCULOSKELETAL DISEASES | |
| MA53329A (fr) | Méthodes de traitement de l'épilepsie | |
| LT3463351T (lt) | Parkinsono ligos gydymas | |
| PL3347002T3 (pl) | Leczenie choroby alzheimera w konkretnej populacji pacjentów | |
| EP3393468A4 (en) | METHOD FOR TREATING AN IMMUNE WEAKNESS | |
| EP3454793A4 (en) | TREATMENT COILS FOR ANEURYSMS | |
| MA46353A (fr) | Méthodes de traitement de l'infertilité féminine | |
| EP3634422A4 (en) | METHOD FOR TREATMENT OF LEUCODYSTROPHIES | |
| EP3546449A4 (en) | PIPERIDINE-2,6-DIKETONE DERIVATIVE AND TREATMENT OF MORBUS CROHN |